NCCN Guidelines Insights: Antiemesis, Version 2.2017.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis address all aspects of management for chemotherapy-induced nausea and vomiting. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Antiemesis, specifically those regarding carboplatin, granisetron, and olanzapine.

PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.

BACKGROUND: Immunotherapeutic approaches to treating cancer have been evaluated during the last few decades with limited success. An understanding of the checkpoint signaling pathway involving the programmed death 1 (PD-1) receptor and its ligands (PD-L1/2) has clarified the role of these approaches in tumor-induced immune suppression and has been a critical advancement in immunotherapeutic drug development. METHODS: A comprehensive literature review was performed to identify the available data on checkpoint inhibitors, with a focus on anti-PD-1 and anti-PD-L1 agents being tested in oncology. The search included Medline, PubMed, the ClinicalTrials.gov registry, and abstracts from the American Society of Clinical Oncology meetings through April 2014. The effectiveness and safety of the available anti-PD-1 and anti-PD-L1 drugs are reviewed. RESULTS: Tumors that express PD-L1 can often be aggressive and carry a poor prognosis. The anti-PD-1 and anti-PD-L1 agents have a good safety profile and have resulted in durable responses in a variety of cancers, including melanoma, kidney cancer, and lung cancer, even after stopping treatment. The scope of these agents is being evaluated in various other solid tumors and hematological malignancies, alone or in combination with other therapies, including other checkpoint inhibitors and targeted therapies, as well as cytotoxic chemotherapy. CONCLUSIONS: The PD-1/PD-L1 pathway in cancer is implicated in tumors escaping immune destruction and is a promising therapeutic target. The development of anti-PD-1 and anti-PD-L1 agents marks a new era in the treatment of cancer with immunotherapies. Early clinical experience has shown encouraging activity of these agents in a variety of tumors, and further results are eagerly awaited from completed and ongoing studies.

Tolerability of Gemcitabine Plus Cisplatin for Treatment of Urothelial Cancer in the Elderly Population.

BACKGROUND: Gemcitabine plus cisplatin is the standard of care for metastatic urothelial cancer and is frequently used in the neoadjuvant and adjuvant setting as well. However, the optimal dose and schedule for patients aged ≥ 65 years is not clear. PATIENTS AND METHODS: We performed a retrospective study to determine the tolerability of gemcitabine plus cisplatin for treatment of urothelial cancer in the elderly population. A total of 28 patients aged ≥ 65 years with urothelial cancer treated with gemcitabine plus cisplatin on a 21-day schedule from January 1, 2008 to August 31, 2013 were included in the present study. RESULTS: Of the 28 patients, 16 (57.1%) received gemcitabine plus cisplatin in the neoadjuvant setting. The most common dosing regimen was gemcitabine 1250 mg/m(2) given on days 1 and 8 plus cisplatin 70 mg/m(2) on day 1 every 21 days, with some receiving gemcitabine at a dose of 1000 mg/m(2). The primary reason behind the dose modifications and treatment delays with the higher gemcitabine dose was hematologic toxicity. Two patients discontinued treatment because of renal dysfunction, with one developing a grade 4 elevation in serum creatinine. One patient developed febrile neutropenia; however, this patient did not receive growth factor support for primary prophylaxis of febrile neutropenia. CONCLUSION: Gemcitabine plus cisplatin overall is a reasonably well-tolerated treatment regimen for patients aged ≥ 65 years. The results of the present study support the use of a lower gemcitabine dose of 1000 mg/m(2), because it was better tolerated.